From First-Line to Third and Beyond: What to Expect for LBCL Treatments

Dr. Brad Hunter is an Associate Professor of Research at Intermountain Health, where he directs the Immune Effector Cell Therapy Program as well as the Oncology Research Program. Since he began leading the program in 2019, Intermountain has rapidly expanded its standard of care and clinical trial footprint, including cellular therapy resources. Dr. Hunter has authored many high-impact publications and presented widely at national academic meetings. He serves on multiple national committees related to CAR T-cell therapy and has written national guidelines for the delivery of cancer care. He completed his MD degree at the University of Rochester School of Medicine and Dentistry, Internal Medicine Residency at the University of California San Francisco, and Medical Oncology Fellowship at the Massachusetts General Hospital/Dana Farber Cancer Institute program of Harvard Medical School. He also holds a Masters’ Degree in Public Health from Brigham Young University.

Hannah joined HealthTree Foundation as the Lymphoma Education Manager in 2024. She is a Certified Health Education Specialist and is passionate about helping patients feel empowered through education and connection. Before joining HealthTree, Hannah worked in healthcare policy helping patients advocate for better care, research, and funding. Hannah enjoys baking and going to concerts in her free time.